LEIDOS BIOMEDICAL RESEARCH, INC. holds $2.3B across 187 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 5 related awards under parent 75N91019D00024. PoP ended Apr 2, 2025 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.
INITIATE THE MANAGEMENT, OVERSIGHT, AND CONDUCT OF THE NIAID DMID CLINICAL TRIAL TITLED "A MULTICENTER, ADAPTIVE, RANDOMIZED BLINDED CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF INVESTIGATIONAL THERAPEUTICS FOR THE TREATMENT OF COVID-19".
Current PoP ended Apr 2, 2025 (481 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Track recompete timing in SCOUT →LEIDOS BIOMEDICAL RESEARCH, INC. — $2.3B obligated across 187 awards (firm-wide, all agencies).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Live Demand-Fit + Displacement scoring, alerts on verdict flips, and watchlists. Free — no card required.
See all live recompete landscapes — who else is expiring, and where the openings are.
Open LEIDOS BIOMEDICAL RESEARCH, INC.’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Register free to start exploring SCOUT →